NZ630581A - Methods for treating hepatitis c - Google Patents
Methods for treating hepatitis cInfo
- Publication number
- NZ630581A NZ630581A NZ630581A NZ63058113A NZ630581A NZ 630581 A NZ630581 A NZ 630581A NZ 630581 A NZ630581 A NZ 630581A NZ 63058113 A NZ63058113 A NZ 63058113A NZ 630581 A NZ630581 A NZ 630581A
- Authority
- NZ
- New Zealand
- Prior art keywords
- hcv
- pyrrolidin
- treating hepatitis
- methods
- benzimidazol
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 241000711549 Hepacivirus C Species 0.000 abstract 5
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 abstract 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 abstract 1
- 238000003205 genotyping method Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702564P | 2012-09-18 | 2012-09-18 | |
| PCT/US2013/060103 WO2014047039A1 (en) | 2012-09-18 | 2013-09-17 | Methods for treating hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ630581A true NZ630581A (en) | 2017-02-24 |
Family
ID=49304326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630581A NZ630581A (en) | 2012-09-18 | 2013-09-17 | Methods for treating hepatitis c |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20140080868A1 (el) |
| EP (2) | EP2897611B1 (el) |
| JP (4) | JP6297044B2 (el) |
| CN (1) | CN104797253A (el) |
| AU (2) | AU2013318302B2 (el) |
| BR (1) | BR112015006037B1 (el) |
| CA (1) | CA2884539C (el) |
| CY (1) | CY1122442T1 (el) |
| DK (1) | DK2897611T3 (el) |
| ES (1) | ES2755089T3 (el) |
| HK (1) | HK1209319A1 (el) |
| HR (1) | HRP20191939T1 (el) |
| HU (1) | HUE046544T2 (el) |
| LT (1) | LT2897611T (el) |
| MX (2) | MX367796B (el) |
| NZ (1) | NZ630581A (el) |
| PL (1) | PL2897611T3 (el) |
| PT (1) | PT2897611T (el) |
| RS (1) | RS59640B1 (el) |
| RU (1) | RU2665365C2 (el) |
| SG (2) | SG11201502095SA (el) |
| SI (1) | SI2897611T1 (el) |
| TW (1) | TWI621436B (el) |
| WO (1) | WO2014047039A1 (el) |
| ZA (1) | ZA201501752B (el) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2897611T (pt) * | 2012-09-18 | 2019-11-27 | Abbvie Inc | Métodos para tratamento da hepatite c |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| AU2014239563B2 (en) * | 2013-03-14 | 2016-05-05 | Abbvie Inc. | Combination of two antivirals for treating hepatitis C |
| CN106413711A (zh) | 2014-04-02 | 2017-02-15 | 艾伯维公司 | 治疗hcv的方法 |
| JP6559701B2 (ja) * | 2014-04-02 | 2019-08-14 | アッヴィ・インコーポレイテッド | Ｈｃｖを処置するための方法 |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| KR102637828B1 (ko) * | 2015-06-26 | 2024-02-20 | 애브비 인코포레이티드 | Hcv의 치료를 위한 고형 약제학적 조성물 |
| MX2018000240A (es) * | 2015-07-08 | 2018-03-14 | Abbvie Inc | Metodos para tratar el vhc. |
| SG10202002900YA (en) * | 2015-07-17 | 2020-05-28 | Abbvie Inc | Solid pharmaceutical compositions for treating hcv |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CA3216359A1 (en) | 2021-04-07 | 2022-10-13 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| GB202113944D0 (en) * | 2021-09-29 | 2021-11-10 | Univ Liverpool | Injectable formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2641859A1 (en) * | 2006-02-09 | 2007-08-16 | Schering Corporation | Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| US9394279B2 (en) * | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| SE1450131A1 (sv) * | 2011-10-21 | 2014-05-07 | Abbvie Inc | DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV |
| PT2897611T (pt) * | 2012-09-18 | 2019-11-27 | Abbvie Inc | Métodos para tratamento da hepatite c |
-
2013
- 2013-09-17 PT PT137734638T patent/PT2897611T/pt unknown
- 2013-09-17 DK DK13773463T patent/DK2897611T3/da active
- 2013-09-17 JP JP2015532139A patent/JP6297044B2/ja active Active
- 2013-09-17 HU HUE13773463A patent/HUE046544T2/hu unknown
- 2013-09-17 RS RS20191378A patent/RS59640B1/sr unknown
- 2013-09-17 NZ NZ630581A patent/NZ630581A/en unknown
- 2013-09-17 RU RU2015114543A patent/RU2665365C2/ru active
- 2013-09-17 PL PL13773463T patent/PL2897611T3/pl unknown
- 2013-09-17 SG SG11201502095SA patent/SG11201502095SA/en unknown
- 2013-09-17 MX MX2015003501A patent/MX367796B/es active IP Right Grant
- 2013-09-17 US US14/029,302 patent/US20140080868A1/en not_active Abandoned
- 2013-09-17 SI SI201331607T patent/SI2897611T1/sl unknown
- 2013-09-17 CA CA2884539A patent/CA2884539C/en active Active
- 2013-09-17 CN CN201380060100.7A patent/CN104797253A/zh active Pending
- 2013-09-17 AU AU2013318302A patent/AU2013318302B2/en active Active
- 2013-09-17 ES ES13773463T patent/ES2755089T3/es active Active
- 2013-09-17 BR BR112015006037-4A patent/BR112015006037B1/pt active IP Right Grant
- 2013-09-17 EP EP13773463.8A patent/EP2897611B1/en active Active
- 2013-09-17 LT LT13773463T patent/LT2897611T/lt unknown
- 2013-09-17 WO PCT/US2013/060103 patent/WO2014047039A1/en active Application Filing
- 2013-09-17 SG SG10201702248UA patent/SG10201702248UA/en unknown
- 2013-09-17 EP EP19187747.1A patent/EP3597190A1/en active Pending
- 2013-09-18 TW TW102133969A patent/TWI621436B/zh active
-
2015
- 2015-03-13 ZA ZA2015/01752A patent/ZA201501752B/en unknown
- 2015-03-18 MX MX2019010600A patent/MX2019010600A/es unknown
- 2015-10-13 HK HK15109967.3A patent/HK1209319A1/xx unknown
-
2018
- 2018-02-19 JP JP2018026645A patent/JP6556884B2/ja active Active
- 2018-05-22 AU AU2018203608A patent/AU2018203608B2/en active Active
-
2019
- 2019-07-11 JP JP2019128933A patent/JP2019194241A/ja active Pending
- 2019-10-24 CY CY20191101109T patent/CY1122442T1/el unknown
- 2019-10-24 HR HRP20191939TT patent/HRP20191939T1/hr unknown
-
2020
- 2020-12-21 JP JP2020211042A patent/JP2021054849A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630581A (en) | Methods for treating hepatitis c | |
| NZ606645A (en) | Anti-viral compounds | |
| NZ710567A (en) | Antiviral compounds | |
| ATE547103T1 (de) | Hemmer des hepatitis-c-virus | |
| EA200900298A1 (ru) | Ингибиторы вируса гепатита с | |
| MX2010008749A (es) | Inhibidores del virus de la hepatitis c. | |
| TN2012000264A1 (en) | Hepatitis c virus inhibitors | |
| TN2012000214A1 (en) | Hepatitis c virus inhibitors | |
| MY152971A (en) | Hepatitis c virus inhibitors | |
| NZ623396A (en) | Methods for treating hcv | |
| MX2012004032A (es) | Compuestos para el tratamiento de hepatitis c. | |
| CL2012001449A1 (es) | Uso de combinaciones del compuesto n-[(ciclopentiloxi)carbonil]-3-metil-l-valiol-(4r)-4-({8-bromo-2-[2-(isobutirilamino)-1,3-tiazol-4-il]-7-metoxi-4-quinolinil}oxi)-n-[(1r,2s)-1-carboxi-2-vinilciclopropil]-l-prolinamida; y envase que comprende las formas de dosificacion. | |
| ATE551337T1 (de) | Inhibitoren des hepatitis-c-virus | |
| MX2013001579A (es) | Inhibidores del virus de la hepatitis c | |
| MX337936B (es) | Compuestos inhibidores del virus de la hepatitis c. | |
| PE20160800A1 (es) | Combinacion de metil ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il-1-pirrolidinil)carbonil)-2-metilpropil)carbamato (daclatasvir) y n-(tert-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida (asunaprevir). | |
| EA201101082A1 (ru) | Ингибиторы вируса гепатита с | |
| MX2010008531A (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| MX2010006489A (es) | Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r) -4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopr opilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida. | |
| MX2012000959A (es) | Inhibidores de los virus flaviviridae. | |
| EA201290576A1 (ru) | Ингибиторы вирусов flaviviridae | |
| EA201391685A1 (ru) | Ингибиторы вируса гепатита с | |
| MX2012008652A (es) | Terapias para tratar infeccion por virus de hepatitis c. | |
| MA34547B1 (fr) | Traitement d'association pour traiter une infection par le vhc | |
| IL225010A (en) | Methyl (2s, 3r) –1 - ((1s) –2 - (- 2 - (- 5 - ((2r, 3r) –1–) (3,5, diplooro – 4– (4– (4 – fluorophenyl) Piperidine-1-ram (phenyl) -5- (6-fluoro-2 - ((2 s) –1- (n- (methoxycarbonyl) - o- methyl- l-thronyl) pyrrolidine-1-ram) -1-benzoimidazole -5-ram (pyrrolidine-2-ram) -6-fluoro-1-h-benzimidazole-2-ram (pyrrolidine-1-ram) -3-methoxy-1-oxobutane-2-ram) carbamate and the pharmacy composition containing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3056812, MATULENKO, MARK A., 1875 COUNTRYSIDE DRIVELIBERTYVILLE, ILLINOIS 60048, US; 3056816, LIU, DACHUN, 1276 GEORGETOWN WAYVERNON HILLS, ILLINOIS 60061, US; 3056817, PRATT, JOHN K., 8210 61ST AVENUEKENOSHA, WISCONSIN 53142, US; 3056819, MARING, CLARENCE J., 1228 W. BORDERS DRIVEPALATINE, ILLINOIS 60067, US; 3138523, KATI, WARREN M., 152 KNOBB HILL LANE, GURNEEILLINOIS 60031, US; 3155377, NG, TERESA (LOK-CHAN), 3229 N. WALKER E.ARLINGTON HEIGHTS, ILLINOIS 60004, US; 3155378, PILOT-MATIAS, TAMI J., 2100 CRANBROOK ROADGREEN OAKS, ILLINOIS 60048, US; 3155379, KRISHNAN, PREETHI, 17718 W. RUNNING CREEK COURTGURNEE, ILLINOIS 60031, US; 3155380, MISTRY, NEETA C. Effective date: 20161202 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2018 BY THOMSON REUTERS Effective date: 20170621 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2019 BY THOMSON REUTERS Effective date: 20180816 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2020 BY THOMSON REUTERS Effective date: 20190817 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2021 BY THOMSON REUTERS Effective date: 20200820 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2022 BY THOMSON REUTERS Effective date: 20210803 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2023 BY THOMSON REUTERS Effective date: 20220801 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2024 BY THOMSON REUTERS Effective date: 20230802 |